Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s

By LabMedica International staff writers
Posted on 27 May 2026

Alzheimer’s disease and Parkinson’s disease are increasing as populations age, yet diagnosis remains largely symptom-driven and often occurs after irreversible brain damage has begun. More...

Earlier detection, ideally through a simple blood test suitable for preventive screening, remains a major clinical priority. By identifying disease-specific protein misfolding in peripheral blood, clinicians may be able to detect pathology before insoluble deposits form. 

At Ruhr University Bochum (Bochum, Germany), investigators developed an immuno-infrared sensor platform designed to capture disease-related biomarkers from body fluids and assess their structural state. The test targets amyloid beta (Aβ) for Alzheimer's disease and alpha-synuclein (α‑Syn) for Parkinson's disease, using antibody-based capture to enrich the proteins of interest. By directly probing folding status, the approach aims to detect neurodegenerative processes well before overt clinical symptoms emerge.

According to the team, misfolding is quantified by modern infrared spectroscopy powered by highly sensitive quantum cascade laser technology. A patented surface chemistry immobilizes the specific antibodies on the sensor, while a dedicated blocking layer minimizes nonspecific adsorption. This configuration enables difference spectroscopy to isolate the secondary‑structure–specific infrared signature of the captured biomarker from the complex background of blood or other body fluids. The group notes that combining molecular biology, biophysics, and laser spectroscopy underpins these measurements and supports scalability through parallel readouts.

The work is featured as a cover story in the April 24, 2026, issue of The Journal of Physical Chemistry B. The immuno-infrared sensor is already being used in clinical studies by BetaSENSE, which provides contract research services for the pharmaceutical industry, including work involving a Parkinson’s disease vaccine. For the blood test to become available as an early detection tool for the general public, approval under the European IVDR Regulation will be required, and the company is working to advance that process.

Related Links
Ruhr University Bochum
betaSENSE


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.